Pathoquest will compare its iDtect blood test with standard testing methods to identify microbes causing infections in patients with febrile neutropenia.
Researchers will use the company's Colvera assay to track biomarkers in rectal cancer patients before, during, and after treatment.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.
Researchers found that ADAR works by stabilizing the FAK gene, which is one of a subset involved in cell migration pathways.
Stat News reports that IBM's Watson for Oncology isn't yet living up to its promise.
Researchers from MSKCC reported today in JAMA that of 1,040 cancer patients referred for germline mutation testing, 18 percent had actionable variants.
This small, for-profit Dutch company has been a driving force behind freeing cBioPortal from Memorial Sloan Kettering, as well as continued development of the software.
Though researchers highlighted their goal of using the method to move toward a test to detect early cancers, their current data speaks only to the method's performance in late-stage cancer patients.
Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.
The company hopes to raise funding this summer and has been conducting pilots with NewYork-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center.
The Guardian reports that visa costs could prevent scientists and others from coming to the UK.
The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.
Nature News says some preprint repositories may close down due to a lack of funds to cover costs.
In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.